ASSESSMENT OF OSTEOPOROSIS AND ANAEMIA RISK IN PATIENTS ON ANTICONVULSANT THERAPY
Keywords:
Key words, Bone mineral density, antiepileptic drug, OsteoporosisAbstract
Objective: To assess the incidence of osteoporosis and anaemia in patients on anticonvulsant therapy and to educate those under risk.
Methods: A prospective observational study was conducted on 50 study participants. The Bone mineral density (BMD), vitamin D, hematological parameters and peripheral smear were noted. Data analyzed using different statistical methods. Patient information brochures for osteoporosis and anaemia were distributed to those on chronic anti-epileptic drug (AED) therapy.
Results: The prevalence of osteoporosis was 16% and osteopenia 22%. The BMD of subjects showed an Insignificant reduction in BMD when compared with a standard reference value for south asian population (*P>0.05). The mean BMD in single therapy group was higher compared with multiple therapy groups. BMD of the enzyme-inducing class was less compared with non-enzyme inducing class but was not significant (P>0.05). Duration of therapy was compared with BMD of patients showed a negative correlation. The relationship between duration of therapy and hematological parameters showed a negative correlation (r =-0.128). The mean haematological parameters in single AED therapy were higher when compared with multiple AED therapy. The study demonstrated 40% microcytic hypochromic and 4% macrocytic hypochromic morphology.
Conclusion: Chronic therapy with AEDs possesses a significant risk of developing osteoporosis and anaemia. The incidence rate varies according to the type, duration, and mode of therapy. Early detection and management through diet exercise or pharmacotherapy will decrease the incidence of unwanted effects due to AEDs and improve the quality of life.
Keywords: Bone mineral density, Antiepileptic drug, Osteoporosis
Downloads
References
G Farhat, B Yamout, MA Mikati, S Demirjian, R Sawaya, El-Hajj Fuleihan. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology 2002;58:1348-53.
Frederick A Klipstein. Subnormal serum folate and macrocytosis with anticonvulsant therapy. Blood 1964;23:68-86.
Alexander Melamed, Eric Vittinghoff, Usha Sriram, Ann V Schwartz, Alka M Kanaya. BMD reference standards among south Asians in the United States. J Clin Densitom 2010;13:379–84.
Richard H Lee, Kenneth W Lyles, Catleen Emeric. A review of the effect of anticonvulsant medications on bone mineral density and fracture risk. Am J Geriatr Pharmacother 2010;8:34-46.
JS Malpas, GH Spray, LJ Witts. Serum folic acid and vitamin B12 levels in anticonvulsant therapy. Br Med J 1966;1:955-7.
Acharya, Suchitra, Bussel, James B. Hematologic toxicity of sodium valproate. J Paediatr Haematol Oncol 2000;22:62-5.
Agneta D Borgstedt, Michael F Bryson, Lionel W Young, Gilbert B Forbes. Long-term administration of antiepileptic drugs and development of rickets. Drug Saf 1972;81:1-9.
Aynaci FM, Orhan F, Orem A, Yildirims S, Gedik Y. Effect of antiepileptic drugs on plasma lipoprotein and other lipid levels in childhood. J Child Neurol 2002;16:367-9.
Berlit P, Krause KH, Heuch CC, Shellenberg B. Serum lipids, and anticonvulsants; Acta Neurol Scand 1982;66:328-34.
Dennis L Andress, Judy Ozuna, David Tirschwell, Lucinda Grande, Meshell Johnson, Arnold F Jacobson, et al. Antiepileptic drug–induced bone loss in young male patients who have seizures. Arch Neurol 2002;59:781-6.
Geda G, H Caksen, D Icagasioglu. Serum lipids, vitamin B12 and folic acid levels in children receiving long-term valproate therapy. Actaneurol Belg 2002;102:122-6.
Hahn TJ, Hendin BA, Scharp CR, Haddad JG. Serum 25-hydroxycalciferol levels and bone mass in children on chronic anticonvulsant therapy. N Engl J Med 1975;292:550–3.
Harinarayan CV, T Ramalakshmi, UV Prasad, D Sudhakar. Vitamin D status in Andhra Pradesh: a population-based study. Med Res 2008;127:211–8.
Ian CK Wong, Samden D Lhatoo. Adverse reactions to new anticonvulsant drugs. Drug Saf 2000;23:35-56.
Barbara G Wells, Joseph T Dipiro, Terry L Schwinghammer. Pharmacotherapy Handbook Eighth edition; 2011. p. 644-69, 20-32, 381-91.
Kim B Handoko, PC Souverein, TP Van Staa, Ronald HB, Hubert GM, TCG Egberts, et al. Risk of aplastic anemia in patients using antiepileptic drugs. Epilepsia 2006;47:1232-6.
Labadarios D, JW Dickerson, DV Parke, EG Lucas, GH Obuwa. The effects of chronic drug administration on hepatic enzyme induction and folate metabolism. Br J Clin Pharmacol 1978;5:167–73.